Singapore National Eye Centre/ Singapore Eye Research Institute
Singapore, 168751
NCT Number: NCT01841580
Approximately 70 million people world-wide are affected with glaucoma, of whom 6.7 million have bilateral blindness.5 Elevated intro-ocular pressure is the major modifiable risk factor in glaucoma, and reducing intraocular pressure to a consistently low level can delay disease progression and therefore, blindness.6 Topical intraocular pressure -lowering medication remains the first-line treatment for glaucoma, with surgical intervention playing a secondary role in cases suboptimally controlled with medication alone.
In this study, we plan to assess the change in tear proteins in trabeculectomy patients before and after operations. It is hoped that this study could help us gain more understanding of the possible mechanism accounting for the development of dry eye disease in glaucoma patients, which could help us develop better screening modalities and therapeutic agents for glaucoma patients at risk to prevent the development of dry eye disease.
Looking for future studies?
Notify Me21 year–99 year
All sexes
Observational
Singapore, 168751
Study Objectives and Purpose
There are two primary aims in this study:
Study Material Human Tears will be collected from patients in SNEC clinic
Study Design:
120 patients will be recruited for this study (details as described below). Schirmers I test, Tear Osmolarity, Tear Break Up Time (TBUT), Anterior segment optical coherence tomography (ASOCT) and Impression cytology will be done during the study visits. Subjective symptom and severity of dry eye disease will be assessed through Visual Analog Scale (VAS).
No. of visits:
There will be 4 visits in this study. Visit 1: Pre-trabeculectomy operation Visit 2: 6 month after trabeculectomy surgery Visit 3: 1 year after trabeculectomy surgery Visit 4: 3 years after trabeculectomy surgery
Selection and Withdrawal of Subjects Recruitment Criteria
Treatment of subjects
Study Procedures:
a) Tear osmolarity will be measured using the osmolarity chip, 3 chips per eye
a) The patient will be asked to look at a target in the instrument while blinking normally. The instrument will scan the lower eyelid margin for imaging of the tear meniscus and conjunctivochalasis
Assessment of efficacy Outcome Measures
Target sample size 120 subjects will be enrolled in the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Time frame: Baseline and 3 years
Time frame: Baseline and 3 years
Time frame: Baseline and 3 years
Time frame: Baseline and 3 years
Time frame: Baseline and 3 years
Singapore National Eye Centre
Other Gov
Long-term Observation of Tear Proteomic Profiles and Ocular Surface in Trabeculectomy Patients Before and After Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06960629
Corneal Diseases, Corneal Edema
Zagreb, Croatia
View Trial DetailsNCT07730424
Eye Diseases, Glaucoma
Fitzroy, Victoria, Australia
View Trial DetailsNCT07168902
Eye Diseases, Glaucoma
Glendale, California, United States
View Trial DetailsNCT04132401
Age-Related Macular Degeneration, Cardiovascular Diseases
Manresa, Barcelona, Spain
View Trial Details